Table 1 Clinical and lung cancer characteristics of included patients
With mediastinoscopy (n=) | Without mediastinoscopy (n=) | |
|---|---|---|
Age, mean (SD)/median (IQR), y | ||
Sex, No. (%) | ||
Male | ||
Female | ||
WHO performance state, No. (%) | ||
WHO 0 | ||
WHO 1 | ||
WHO 2 | ||
WHO 3 | ||
WHO 4 | ||
ASA classification, No. (%) | ||
ASA-1 | ||
ASA-2 | ||
ASA-3 | ||
ASA-4 | ||
Tumour location, No. (%) | ||
Left lower lobe | ||
Left upper lobe | ||
Right lower lobe | ||
Right middle lobe | ||
Right upper lobe | ||
Tumour stage FDG-PET/CT, No. (%) | ||
T | ||
Nodal stage FDG-PET/CT, No. (%) | ||
N | ||
Indication for invasive mediastinal nodal staging, No. (%) | ||
Clinical N1-3 | ||
Central tumour | ||
FDG-non-avid tumour | ||
Peripheral tumour > 3 cm | ||
Final histopathology, No. (%) | ||
NSCLC | ||
Subtype | ||
Small cell carcinoma | ||
Benign | ||